Loading
Zoledronic acid (Zometa) is a fifteen-minute infusion given every few weeks or months to strengthen bone and prevent fractures, spinal cord compression and the need for radiotherapy in people with myeloma or cancer that has spread to bone; it also treats dangerously high calcium caused by cancer.
Zoledronic acid was approved by the FDA in August 2001 for hypercalcaemia of malignancy (two randomised trials against pamidronate showed faster and more complete normalisation of calcium) and in 2002 for multiple myeloma and bone metastases from solid tumours in conjunction with antineoplastic therapy, on trials in breast cancer, prostate cancer, lung and other solid tumours that reduced skeletal-related events. The EU authorised Zometa in 2001. Every-12-week dosing was shown non-inferior to monthly (CALGB 70604), and adjuvant zoledronic acid reduces recurrence and death in postmenopausal early breast cancer (EBCTCG meta-analysis), an off-label but guideline-endorsed use. Osteonecrosis of the jaw, renal impairment (dose adjustment and creatinine monitoring) and acute-phase reactions after the first dose are the main risks. Denosumab is the alternative when renal function is poor.
Binds bone mineral and inhibits farnesyl pyrophosphate synthase in osteoclasts, blocking prenylation of signalling proteins and inducing osteoclast apoptosis; reduces bone resorption and calcium release.
1.Zoledronic acid slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2001 | Hypercalcaemia of malignancy |
| US | 2002 | Multiple myeloma and bone metastases from solid tumours, with antineoplastic therapy |
| EU | 2001 | Prevention of skeletal-related events in advanced malignancies involving bone; tumour-induced hypercalcaemia |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Zoledronic acid" OR ABSTRACT:"Zoledronic acid" OR TITLE:"Zometa" OR ABSTRACT:"Zometa" OR TITLE:"Reclast / Aclasta osteoporosis formulation" OR ABSTRACT:"Reclast / Aclasta osteoporosis formulation" OR TITLE:"Zoledronate" OR ABSTRACT:"Zoledronate") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Zoledronic acid, not a curated reading list.
Shares Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma, Palliation in advanced triple-negative breast cancer: brain, bone, pleura, skin and end of life, Bone metastases and skeletal-related events, Multiple myeloma and the tags generic, supportive.
Shares HR-positive / HER2-negative breast cancer and the tags generic, supportive.
Shares Prostate cancer and the tags generic, supportive.
Shares the tags generic, supportive.
Shares the tags generic, supportive.
Shares the tags generic, supportive.
Shares Palliation in lung cancer: breathlessness, pleural effusion, blocked airway, bone and brain, Bone-modifying agents (bisphosphonates, denosumab), Bone metastases and skeletal-related events, Multiple myeloma and the tag supportive.
Shares Palliation in advanced triple-negative breast cancer: brain, bone, pleura, skin and end of life, Palliation in lung cancer: breathlessness, pleural effusion, blocked airway, bone and brain, Metastatic cancer (cancer that has spread), Lung cancer (all types) and the tag supportive.